GGrantIndex
← Leaderboards

Tsuneya Ikezu

University Of Nebraska Medical Center

$21,200,838
Attributed
$25,151,788
Total exposure
15
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.5M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$25,151,788 · 15

By mechanism

R01$15,658,832 · 8
RF1$7,017,202 · 2
R21$888,688 · 2
R56$832,623 · 1
P01$705,543 · 1
P20$48,900 · 1

Top collaborators

Most similar at University Of Nebraska Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos

Research focus

Alzheimer&AposS DiseaseNeuronsCellsBrainMediatingProteinsMolecularBaseMicrogliaIn VivoPathologyMouse ModelAnimal ModelBrain TissueDisease ProgressionInflammatoryExtracellular VesiclesNeurodegenerative DisordersCell TypeSamplingTau ProteinsAstrocytesSymptoms

Grant awards (47)

APOE and microglia-mediated progression in tau pathology in AD$721,020
R01 · FY2025 · AG · contact PI
Molecular characterization of extracellular vesicles for the spread of misfolded tau protein$599,164
R01 · FY2025 · AG · contact PI
Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model$522,234
R01 · FY2025 · AG · contact PI
APOE and microglia-mediated progression in tau pathology in AD$727,596
R01 · FY2024 · AG · contact PI
Molecular characterization of extracellular vesicles for the spread of misfolded tau protein$611,392
R01 · FY2024 · AG · contact PI
Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model$532,892
R01 · FY2024 · AG · contact PI
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease$391,250
R01 · FY2024 · AG · contact PI
Tumor susceptibility gene 101, a new microglial therapy candidate for Alzheimer’s disease to prevent cognitive decline$1,994,202
RF1 · FY2023 · AG
Molecular characterization of extracellular vesicles for the spread of misfolded tau protein$611,392
R01 · FY2023 · AG · contact PI
Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model$532,892
R01 · FY2023 · AG · contact PI
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease$391,250
R01 · FY2023 · AG · contact PI
Molecular characterization of extracellular vesicles for the spread of misfolded tau protein$611,392
R01 · FY2022 · AG · contact PI
Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model$532,892
R01 · FY2022 · AG · contact PI
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease$391,250
R01 · FY2022 · AG · contact PI
APOE and microglia-mediated progression in tau pathology in AD$2,151,974
RF1 · FY2021 · AG · contact PI
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s disease$809,297
R01 · FY2021 · AG
Molecular characterization of extracellular vesicles for the spread of misfolded tau protein$625,498
R01 · FY2021 · AG · contact PI
Assessment of a novel tau propagation pathway from layer II medial entorhinal cortical neurons to CA1 pyramidal neurons as an early Braak stage mouse model$532,892
R01 · FY2021 · AG · contact PI
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease$391,250
R01 · FY2021 · AG · contact PI
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer's disease$809,297
R01 · FY2020 · AG
Targeting emerging P2RX7 signaling pathways in animal models of Alzheimer's disease$412,500
R01 · FY2020 · AG · contact PI
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s disease$813,171
R01 · FY2019 · AG
Identification of exosome signature in serum from ALS patients$242,406
R21 · FY2019 · NS
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s disease$812,962
R01 · FY2018 · AG
Identification of exosome signature in serum from ALS patients$300,740
R21 · FY2018 · NS
Biogenesis of Exosomes, Secretion, and Trafficking in Alzheimer's Disease$832,623
R56 · FY2017 · AG
Targeting the miR-155 and APOE-TREM2 pathways to restore dysfunctional microglia in Alzheimer’s disease$828,613
R01 · FY2017 · AG
Exosome-mediated propagation of pathogenic tau protein$2,871,026
RF1 · FY2016 · AG · contact PI
Cells and Tissue Core$135,773
P01 · FY2012 · NS · contact PI
Cells and Tissue Core$136,800
P01 · FY2011 · NS · contact PI
In Vivo Reconstitution Models for NeuroAIDS and Beta-Amyloidosis$393,771
R01 · FY2010 · MH · contact PI
Cells and Tissue Core$139,707
P01 · FY2010 · NS · contact PI
Anti-inflammatory regulation of beta-amyloidosis$98,030
R21 · FY2010 · AG · contact PI
Anti-inflammatory regulation of beta-amyloidosis$58,174
R21 · FY2010 · AG · contact PI
In Vivo Reconstitution Models for NeuroAIDS and Beta-Amyloidosis$371,250
R01 · FY2009 · MH · contact PI
OTK18 Regulation in HIV-1 associated dementia$243,920
R01 · FY2009 · MH · contact PI
Anti-inflammatory regulation of beta-amyloidosis$189,338
R21 · FY2009 · AG · contact PI
Cells and Tissue Core$152,142
P01 · FY2009 · NS · contact PI
OTK18 Regulation in HIV-1 associated dementia$243,920
R01 · FY2008 · MH · contact PI
Cells and Tissue Core$141,121
P01 · FY2008 · NS · contact PI
OTK18 Regulation in HIV-1 associated dementia$243,920
R01 · FY2007 · MH · contact PI
GENOME-WIDE SCREENING OF HOST GENES INVOLVED IN VIRUS-INDUCED NEUROTOXIC SIGNALI$48,900
P20 · FY2007 · RR · contact PI
OTK18 Regulation in HIV-1 associated dementia$251,205
R01 · FY2006 · MH · contact PI
OTK18 Regulation in HIV-1 associated dementia$257,250
R01 · FY2005 · MH
AntiRetroviral Activities of NEBRI$147,000
R01 · FY2003 · AI
AntiRetroviral Activities of NEBRI$147,000
R01 · FY2002 · AI
AntiRetroviral Activities of NEBRI$147,500
R01 · FY2001 · AI